{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:56:25Z","timestamp":1789473385185,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Intramural Research Program of Center for Cancer Research, National Cancer Institute","award":["BC011486"],"award-info":[{"award-number":["BC011486"]}]},{"name":"Intramural Research Program of Center for Cancer Research, National Cancer Institute","award":["SC006738"],"award-info":[{"award-number":["SC006738"]}]},{"name":"NIH","award":["R01AI112417"],"award-info":[{"award-number":["R01AI112417"]}]},{"name":"NIH","award":["R01AI076119"],"award-info":[{"award-number":["R01AI076119"]}]},{"name":"JSPS KAKENHI","award":["JP16K08826"],"award-info":[{"award-number":["JP16K08826"]}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP18fk0410015"],"award-info":[{"award-number":["JP18fk0410015"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP18fk0310113"],"award-info":[{"award-number":["JP18fk0310113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Center for Global Health and Medicine Research Institute","award":["H29-1010"],"award-info":[{"award-number":["H29-1010"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.chembiol.2018.07.014","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T15:06:44Z","timestamp":1535641604000},"page":"1268-1278.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The High Genetic Barrier of EFdA\/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase"],"prefix":"10.1016","volume":"25","author":[{"given":"Yuki","family":"Takamatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debananda","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kohgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole S.","family":"Delino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan G.","family":"Sarafianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2018.07.014_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2018.07.014_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group","volume":"27","author":"Allen","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.chembiol.2018.07.014_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/135965350400900203","article-title":"Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations","volume":"9","author":"Bartholomeusz","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.chembiol.2018.07.014_bib4","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1073\/pnas.97.7.3056","article-title":"Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase","volume":"97","author":"Boyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2018.07.014_bib5","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1371\/journal.ppat.0020010","article-title":"Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance","volume":"2","author":"Boyer","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chembiol.2018.07.014_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/hiv.09.40","article-title":"The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications","volume":"3","author":"Brenner","year":"2009","journal-title":"HIV Ther."},{"key":"10.1016\/j.chembiol.2018.07.014_bib7","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/JVI.75.10.4771-4779.2001","article-title":"Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC)","volume":"75","author":"Das","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chembiol.2018.07.014_bib8","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Fernandez-Fernandez","year":"2011","journal-title":"AIDS Res. Treat."},{"key":"10.1016\/j.chembiol.2018.07.014_bib9","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1128\/AAC.00270-09","volume":"53","author":"Hattori","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.282.5394.1669","article-title":"Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance","volume":"282","author":"Huang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2018.07.014_bib11","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.biocel.2008.04.007","article-title":"2\u02b9-Deoxy-4\u02b9-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants","volume":"40","author":"Kawamoto","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.chembiol.2018.07.014_bib12","doi-asserted-by":"crossref","first-page":"13315","DOI":"10.1016\/S0040-4020(97)00844-2","article-title":"Synthesis of 4\u02b9-C-fluoromethylnucleosides\u00a0as potential antineoplastic agents","volume":"53","author":"Kitano","year":"1997","journal-title":"Tetrahedron"},{"key":"10.1016\/j.chembiol.2018.07.014_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/nass\/44.1.105","article-title":"Synthesis of 4\u02b9-ethynyl-purine nucleosides possessing anti-HIV activity","volume":"44","author":"Kitano","year":"2000","journal-title":"Nucleic Acids Symp. Ser."},{"key":"10.1016\/j.chembiol.2018.07.014_bib14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1128\/AAC.45.5.1539-1546.2001","article-title":"4\u02b9-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in\u00a0vitro","volume":"45","author":"Kodama","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib15","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1271\/bbb.63.1146","article-title":"Synthesis of 4\u02b9-C-ethynyl-beta-D-arabino- and 4\u02b9-C-ethynyl-2\u02b9-deoxy-beta-D-ribo-pentofuranosyl pyrimidines, and their biological evaluation","volume":"63","author":"Kohgo","year":"1999","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.chembiol.2018.07.014_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/nass\/42.1.127","article-title":"Synthesis of 4\u02b9-substituted nucleosides and their biological evaluation","volume":"42","author":"Kohgo","year":"1999","journal-title":"Nucleic Acids Symp. Ser."},{"key":"10.1016\/j.chembiol.2018.07.014_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1081\/NCN-120037508","article-title":"Design, efficient synthesis, and anti-HIV activity of 4\u02b9-C-cyano- and 4\u02b9-C-ethynyl-2\u02b9-deoxy purine nucleosides","volume":"23","author":"Kohgo","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.chembiol.2018.07.014_bib18","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1002\/slct.201800527","article-title":"Synthesis of 4\u02b9-substituted purine 2\u02b9-deoxynucleosides and their activity against human immunodeficiency virus type 1 and hepatitis B virus","volume":"3","author":"Kohgo","year":"2018","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.chembiol.2018.07.014_bib19","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1073\/pnas.86.13.4803","article-title":"Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity","volume":"86","author":"Larder","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2018.07.014_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/infdis\/jit006","article-title":"Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging","volume":"207","author":"Leeansyah","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chembiol.2018.07.014_bib21","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/jm00086a013","article-title":"Synthesis and anti-HIV activity of 4\u02b9-azido- and 4\u02b9-methoxynucleosides","volume":"35","author":"Maag","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2018.07.014_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3851\/IMP2697","article-title":"Delayed emergence of HIV-1 variants resistant to 4\u02b9-ethynyl-2-fluoro-2\u02b9-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001","volume":"19","author":"Maeda","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.chembiol.2018.07.014_bib23","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/AAC.00816-06","article-title":"In\u00a0vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine","volume":"50","author":"Margot","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib24","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1073\/pnas.85.8.2469","article-title":"Sequence comparisons of retroviral proteins: relative rates of change and general phylogeny","volume":"85","author":"McClure","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2018.07.014_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.chembiol.2018.07.014_bib26","doi-asserted-by":"crossref","first-page":"35681","DOI":"10.1074\/jbc.M109.036616","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by 4\u02b9-ethynyl-2-fuoro-2\u02b9-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor","volume":"284","author":"Michailidis","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chembiol.2018.07.014_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1742-4690-10-65","article-title":"Hypersusceptibility mechanism of tenofovir-resistant HIV to EFdA","volume":"10","author":"Michailidis","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.chembiol.2018.07.014_bib28","first-page":"22","article-title":"K65R, TAMs and tenofovir","volume":"6","author":"Miller","year":"2004","journal-title":"AIDS Rev."},{"key":"10.1016\/j.chembiol.2018.07.014_bib29","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1128\/AAC.00723-12","article-title":"Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4\u02b9-ethynyl-2-fluoro-2\u02b9-deoxyadenosine in\u00a0vitro and in\u00a0vivo","volume":"56","author":"Murphey-Corb","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib30","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1128\/AAC.00277-07","article-title":"Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on\u00a0human DNA polymerases of 4\u02b9-ethynyl-2-fluoro-2\u02b9-deoxyadenosine","volume":"51","author":"Nakata","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib31","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1128\/AAC.49.8.3355-3360.2005","article-title":"Anti-human immunodeficiency virus type 1 activity and resistance profile of 2\u02b9,3\u02b9-didehydro-3\u02b9-deoxy-4\u02b9-ethynylthymidine in\u00a0vitro","volume":"49","author":"Nitanda","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib32","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1021\/jm990050i","article-title":"Nucleosides and nucleotides. 185. Synthesis and biological activities of 4\u02b9\u03b1-C-branched-chain sugar pyrimidine nucleosides","volume":"42","author":"Nomura","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2018.07.014_bib33","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1021\/jm000209n","article-title":"Syntheses of 4\u02b9-C-ethynyl-\u03b2-D-arabino- and 4\u02b9-C-ethynyl-2\u02b9-deoxy-\u03b2-D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity","volume":"43","author":"Ohrui","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2018.07.014_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2183\/pjab.87.53","article-title":"Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants","volume":"87","author":"Ohrui","year":"2011","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.chembiol.2018.07.014_bib35","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/jac\/dkx280","article-title":"M184I\/V substitutions and E138K\/M184I\/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA","volume":"72","author":"Oliveira","year":"2017","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0040-4039(00)77667-2","article-title":"Synthesis of 4\u02b9-cyanothymidine and analogs as potent inhibitors of HIV","volume":"33","author":"O-Yang","year":"1992","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.chembiol.2018.07.014_bib37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11904-012-0119-7","article-title":"Osteoporosis and bone health in HIV","volume":"9","author":"Powderly","year":"2012","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.chembiol.2018.07.014_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0042-6822(89)90242-0","article-title":"Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein","volume":"173","author":"Rey","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.chembiol.2018.07.014_bib39","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation defective RT inhibitor 4\u02b9-ethynyl-2-fluoro-2\u02b9-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2018.07.014_bib40","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1128\/AAC.01326-15","article-title":"The nucleoside analog BMS-986001 shows greater in\u00a0vitro activity against HIV-2 than against HIV-1","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/jhep.2001.22166","article-title":"Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region","volume":"33","author":"Stuyver","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.chembiol.2018.07.014_bib42","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep.27962","article-title":"4\u02b9-Modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus","volume":"62","author":"Takamatsu","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.chembiol.2018.07.014_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.virol.2011.11.004","article-title":"The impact of molecular manipulation in residue 114 of human immunodeficiency virus type-1 reverse transcriptase on dNTP substrate binding and viral replication","volume":"422","author":"Van Cor-Hosmer","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.chembiol.2018.07.014_bib44","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jmv.24395","article-title":"Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE","volume":"88","author":"Van Eygen","year":"2016","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.chembiol.2018.07.014_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00744-17","article-title":"MK-8591 (4\u02b9-ethynyl-2-fluoro-2\u02b9-deoxyadenosine) exhibits potent activity against HIV-2 isolates and drug-resistant HIV-2 mutants in culture","volume":"61","author":"Wu","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.chembiol.2018.07.014_bib46","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41598-018-19602-9","article-title":"HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir","volume":"8","author":"Yasutake","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945618302666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945618302666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T23:00:23Z","timestamp":1661900423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945618302666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S2451945618302666"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2018.07.014","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The High Genetic Barrier of EFdA\/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2018.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}